| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.19 | 2e-05 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.17 | 0.0001 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.45 | 0.0005 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.18 | 0.0008 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.44 | 0.001 |